Globus Medical (GMED) announced preliminary 4Q17 sales of US $175.5MM, +15.8% vs. 4Q16, and 2017 sales of $635.4MM, +12.7% vs. 2016. Full-year revenue exceeds previously-stated guidance of $625.0MM.
While full detail will be available in the final results to be published in late February, leadership noted that 4Q growth was 100% organic, as the anniversary of its acquisition of Alphatec’s ex-U.S. business passed in September 2017. Growth was supported by U.S. spine revenue, sales in Japan and strong robotic sales.
GMED will use cash made available following U.S. tax legislation changes in part to increase spending on its Emerging Technologies, which include trauma and robotics, by $14.0MM in 2018.
For 2018, GMED established full-year revenue guidance of $690.0MM.
Globus Medical (GMED) announced preliminary 4Q17 sales of US $175.5MM, +15.8% vs. 4Q16, and 2017 sales of $635.4MM, +12.7% vs. 2016. Full-year revenue exceeds previously-stated guidance of $625.0MM.
While full detail will be available in the final results to be published in late February, leadership noted that 4Q growth was 100% organic, as...
Globus Medical (GMED) announced preliminary 4Q17 sales of US $175.5MM, +15.8% vs. 4Q16, and 2017 sales of $635.4MM, +12.7% vs. 2016. Full-year revenue exceeds previously-stated guidance of $625.0MM.
While full detail will be available in the final results to be published in late February, leadership noted that 4Q growth was 100% organic, as the anniversary of its acquisition of Alphatec’s ex-U.S. business passed in September 2017. Growth was supported by U.S. spine revenue, sales in Japan and strong robotic sales.
GMED will use cash made available following U.S. tax legislation changes in part to increase spending on its Emerging Technologies, which include trauma and robotics, by $14.0MM in 2018.
For 2018, GMED established full-year revenue guidance of $690.0MM.
Copy to clipboard 
